Hybrid Products: Navigating Ambiguity in ATMP Classification Hybrid Products: Navigating Ambiguity in ATMP Classification The evolving landscape of Advanced Therapy Medicinal Products (ATMPs) necessitates a thorough understanding of their classification, especially as it pertains to hybrid products. Hybrid products often sit at the confluence of different regulatory frameworks, causing uncertainty in their approval processes. This article provides a thorough, step-by-step tutorial for regulatory affairs professionals navigating the complexities of ATMP classification within the context of hybrid products. The content focuses primarily on the U.S. landscape but also aligns with EMA and other global regulatory considerations. Step 1: Understanding ATMPs and…

FDA vs EMA ATMP Classification Consulting in 2023: Borderline Product Strategy and Documentation FDA vs EMA ATMP Classification Consulting in 2023: Borderline Product Strategy and Documentation In the rapidly evolving landscape of Advanced Therapy Medicinal Products (ATMPs), understanding how to navigate the complexities of regulatory classifications between the FDA and EMA is crucial for organizations involved in product development. This guide serves as a comprehensive step-by-step tutorial for regulatory affairs professionals looking into EMA ATMP regulatory consulting, including detailed pathways, documentation standards, and compliance requirements essential for achieving successful product classifications. By following the outlined steps, professionals can ensure that…

How to Prepare an EMA CAT Classification Dossier in 2023: Evidence Checklist and Templates How to Prepare an EMA CAT Classification Dossier in 2023: Evidence Checklist and Templates As the landscape for Advanced Therapy Medicinal Products (ATMPs) becomes increasingly complex, pharmaceutical professionals must understand the regulatory pathways applicable to these innovative therapies. This comprehensive guide outlines the step-by-step process for preparing a classification dossier for the EMA’s Committee for Advanced Therapies (CAT). With a focus on practical actions, documentation expectations, and best practices, this article serves as an essential resource for regulatory affairs specialists. The primary keyword for this article…

ATMP Classification Risk Register for US Sponsors: Avoiding Late Reclassification in 2023 ATMP Classification Risk Register for US Sponsors: Avoiding Late Reclassification in 2023 As the biopharmaceutical landscape evolves, the classification of Advanced Therapy Medicinal Products (ATMPs) has become increasingly complex. With the growing interest in cell and gene therapies, it is imperative for US sponsors to create a robust ATMP Classification Risk Register to ensure compliance with FDA and EMA regulatory requirements. This guide outlines a step-by-step approach to developing this essential document, helping to mitigate the risk of late reclassification that may impede development and commercialization plans. Step…

ATMP vs HCT/P 361 vs 351: US FDA Decision Tree for Cell and Tissue Products in 2023 ATMP vs HCT/P 361 vs 351: US FDA Decision Tree for Cell and Tissue Products in 2023 The regulation of advanced therapy medicinal products (ATMPs) and human cells, tissues, and cellular and tissue-based products (HCT/Ps) by the U.S. FDA is complex and multifaceted. In this comprehensive guide, we provide a step-by-step tutorial that delineates the key considerations for organizations navigating the ATMP landscape versus HCT/P categorization, specifically referring to 361 and 351 pathways. This guide is geared towards regulatory affairs professionals seeking thorough…

Scientific Advice Strategy for ATMP Classification: Meeting Pack for 2023 Scientific Advice Strategy for ATMP Classification: Meeting Pack for 2023 Advanced Therapy Medicinal Products (ATMPs) represent a significant innovation in the treatment landscape, enabling new therapeutic strategies primarily for serious and chronic diseases. To navigate the complex regulatory framework, organizations must implement an effective strategy for ATMP classification. This article provides a comprehensive step-by-step tutorial on developing a Scientific Advice strategy tailored for ATMP classification, particularly focusing on European Medicines Agency (EMA) guidelines, and ensuring compliance and strategic planning in the regulatory submission process. Step 1: Understanding ATMP Classification Criteria…